Clinical Trial

Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 9, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
Researchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take the standard of care (SOC), lonafarnib, and will be randomized to either take SOC alone or in combination with progerinin.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-09; most recent amendment 2026-02-05.
Status change: Recruiting → Active, Not Recruiting 2026-01-21
Trial Details
NCT Number NCT06775041
Lead Sponsor PRG Science & Technology Co., Ltd.
Conditions Hutchinson-Gilford Progeria Syndrome
Enrollment 10 participants
Start Date 2025-01-13
Primary Completion 2026-03 (estimated)
Study Completion 2026-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-09